Kailera Therapeutics (NASDAQ:KLRA) Posts Earnings Results, Beats Expectations By $0.81 EPS

Kailera Therapeutics (NASDAQ:KLRA) released its quarterly earnings data on Wednesday. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($1.55) by $0.81, FiscalAI reports.

Kailera Therapeutics Stock Performance

Shares of KLRA traded down $0.57 during trading hours on Thursday, hitting $12.23. The company had a trading volume of 366,794 shares, compared to its average volume of 881,449. The stock has a fifty day moving average price of $13.01. The stock has a market capitalization of $1.59 billion and a price-to-earnings ratio of -0.00. Kailera Therapeutics has a 12 month low of $9.76 and a 12 month high of $28.23.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Kailera Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $42.75.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Commonwealth Equity Services LLC bought a new stake in shares of Kailera Therapeutics during the third quarter worth approximately $134,000. Tidal Investments LLC bought a new position in shares of Kailera Therapeutics during the second quarter worth approximately $309,000. Profund Advisors LLC bought a new position in shares of Kailera Therapeutics during the third quarter worth approximately $216,000. Squarepoint Ops LLC bought a new position in shares of Kailera Therapeutics during the second quarter worth approximately $993,000. Finally, Mirador Capital Partners LP acquired a new stake in Kailera Therapeutics during the 3rd quarter worth approximately $666,000.

About Kailera Therapeutics

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and related metabolic diseases.

The company’s activities center on the research and development of potential pharmaceutical therapies intended to address chronic weight management and associated health conditions. Its products remain in development and are subject to clinical, regulatory and commercial milestones.

Publicly available information about Kailera Therapeutics’ specific product candidates, operating geographies and leadership is limited.